Ondansetron Hexal (Ondansetron)

Ondansetron Hexal is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting associated with several clinical pathways.

• Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes.
• Radiation‑induced nausea and vomiting: helps control symptoms during and after radiotherapy.
• Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures.
• Pregnancy‑related hyperemesis gravidarum (off‑label): may be considered when conventional therapies are ineffective.
• Anticipatory nausea: used in patients who develop nausea in anticipation of chemotherapy sessions.

• Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal nerve terminals in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these receptors, it interrupts the neural signaling cascade that initiates the vomiting reflex, thereby reducing nausea and vomiting associated with chemotherapy, radiation, and surgery.

Side effects of ondansetron are generally mild but can vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements or hard stools.
• Diarrhoea: loose stools occurring intermittently.
• Fatigue: feeling unusually tired or weak.
• Dizziness: light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, including QT prolongation.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Serotonin syndrome: agitation, hyperreflexia, tremor, or fever when combined with other serotonergic agents.
• Hepatic dysfunction: elevated liver enzymes indicating liver stress.
• Vision changes: blurred vision or visual disturbances.

When using Ondansetron Hexal, consider the following safety measures:

• Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed.
• Electrolyte assessment: correct potassium, magnesium, or calcium abnormalities before administration.
• Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome.
• Pregnancy and lactation: use only if the potential benefit outweighs the risk.
• Pediatric use: dose adjustments may be required based on weight and age.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ondansetron may interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Aprepitant: combined use can increase the risk of QT prolongation.
• Certain anti‑arrhythmic drugs (e.g., amiodarone, quinidine): additive effect on cardiac conduction.
• Tramadol and other serotonergic analgesics: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): modest increase in exposure.
• Oral contraceptives: potential reduction